EMA has announced some organizational adjustments and strategic amendments of its corporate management structure that are aimed at creating a leaner, more streamlined architecture and improved administrative support. The main changes include:
- Reduction of the number of divisions dealing with human medicines from four to three, with one division responsible for support to medicines developers; one for the evaluation of medicines, bringing scientific and procedure management under one umbrella; and one for the oversight of medicines, including pharmacovigilance and inspection;
- Creation of a new function dedicated to strengthening the collaboration between EMA and the national competent authorities by overseeing the implementation of the joint network strategy to 2020, promoting innovation in regulatory science across the European regulatory system for medicines, and addressing the increasing complexity of the committees' activities coordination; and
- Streamlining the division dealing with administration and corporate management through separate entities for strategic planning, budgeting and monitoring, finance and procurement, and support to staff and delegates.
It is not anticipated that interactions between stakeholders and the Agency will be affected by these changes.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
